Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers
Authors:
- 4 March 2020
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (9) , 417-425
Abstract
Gene fusions involving NTRK1, NTRK2 and NTRK3 are oncogenic drivers across a wide variety of cancer types. Inhibitors of the chimeric TRKA/B/C protein kinases encoded by these fusions are now avail...Keywords
Funding Information
- GD Demetri
- G1 Therapeutics
- Caris Life Sciences
- ERASCA Pharmaceuticals
- Champions Oncology
- National Institutes of Health
This publication has 40 references indexed in Scilit:
- Tyrosine kinase gene rearrangements in epithelial malignanciesNature Reviews Cancer, 2013
- Unmasking MASC: Bringing to Light the Unique Morphologic, Immunohistochemical and Genetic Features of the Newly Recognized Mammary Analogue Secretory Carcinoma of Salivary GlandsHead and Neck Pathology, 2013
- Administration of a Tropomyosin Receptor Kinase Inhibitor Attenuates Sarcoma-Induced Nerve Sprouting, Neuroma Formation and Bone Cancer PainMolecular Pain, 2010
- Regulation of preimplantation embryo development by brain-derived neurotrophic factorDevelopmental Biology, 2007
- Identification of a Switch in Neurotrophin Signaling by Selective Tyrosine PhosphorylationJournal of Biological Chemistry, 2006
- Neurotrophins and their receptors: A convergence point for many signalling pathwaysNature Reviews Neuroscience, 2003
- Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF responsesNeuron, 1994
- The trk proto-oncogene encodes a receptor for nerve growth factorCell, 1991
- Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGFNature, 1991
- A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequencesNature, 1986